狄诺塞麦的价格

It is the first approved monoclonal antibody specifically targeting RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. The mRNA of human RANKL is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Osteoclasts are responsible for bone resorption, and osteoclast precursors must have low levels of macrophage colony-stimulating factor and RANKL during their differentiation into mature osteoclasts. This product has a high affinity with RANKL, prevents RANK ligand from activating RANK on the surface of osteoclasts, inhibits osteoclast activation and development, reduces bone resorption, increases bone density and bone strength of both cortical bone and trabecular bone, promotes bone reconstruction, and reduces the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

On May 27, 2019, Amgen China announced today that denosumab has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or that may result in severe functional disability after surgical resection, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and a body weight ≥45 kg). In 2018, denosumab was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

Since the therapeutic effect of denosumab is so significant, how much does it cost?

Although the country conditionally approved the marketing of denosumab in May 2019, because it was conditionally approved and it was only on the market for five months, the domestic selling price of this drug cannot be collected. What is certain is that as an imported original drug, new drug, and special effect drug, the price of denosumab in China must be very high. According to the editor of Medical Companion Travel, the current specification of denosumab on the market in the United States is 60mg/1ml tube/box, priced at US$1,169.98. The price is relatively expensive, and most families of patients with average economic levels cannot afford the high medical expenses. Fortunately, denosumab produced by Amgen of the United States has been launched in Turkey. The specification is 125mg/1ml tube/box. The price is equivalent to RMB 3,000, which can be said to be high quality and low price. Therefore, more and more patients choose the American drug Amgen launched in Türkiye.